Oura Health Oy announced the postponement of its initial public offering (IPO) on Tuesday due to "uncertainty" in market conditions, despite claiming there was "strong demand" for its stock. This move highlights a growing trend of IPO delays in 2026, attributed largely to rising bond yields, according to analysts. Matthew Kennedy, a senior strategist at Renaissance Capital, noted the significance of multiple companies delaying their offerings, suggesting that these decisions reflect broader market conditions rather than isolated company issues.
Read More
In the past week, four companies, all seeking to raise at least $50 million, either postponed or withdrew their IPOs. This brings the total number of postponements in the third quarter to seven, an increase from four in the second quarter and three in the first. Prior to Oura's announcement, Holtec Nuclear and Amaero also postponed their IPOs, while Bamboo Insurance announced its delay on September 22.
Jay Ritter, director of the IPO Initiative at the University of Florida, expressed understanding for companies citing market conditions as a reason for postponing their IPOs, noting the trend suggests a broader issue affecting multiple firms.
Despite the recent delays, 2026 has been a robust year for IPOs, with approximately $146.9 billion raised across 110 deals, excluding special purpose acquisition companies. This marks a 394% increase in total proceeds compared to last year, although the number of IPOs is down 30% from the previous year’s totals. Health care and industrial sectors lead year-to-date IPO activities, each occupying 24% of total offerings, while technology accounts for 18%.
According to Renaissance analysts, concerns regarding artificial intelligence spending, high bond yields, and continued rate hikes have contributed to lower IPO activity in the third quarter. Investors currently harbor caution towards consumer-focused products, as highlighted by Gil Luria, head of technology research at DA Davidson, who pointed out that firms like Oura are facing skepticism due to investor wariness following poor performances of similar products.
Furthermore, companies now have greater access to private capital, allowing them to explore alternatives to public offerings without needing to compromise on valuation, according to Ian Schuman from Latham and Watkins.